Common heart failure drug reduces risk of chemotherapy-induced heart damage in cancer patients

A commonly prescribed medication for heart failure was linked to a lower risk of heart damage, or cardiotoxicity, among high-risk cancer patients undergoing chemotherapy treatment using anthracyclines, according to preliminary late-breaking science presented today at the American Heart Association’s Scientific Sessions 2024.

Study identifies mechanism that impedes the effectiveness of melanoma therapies

In many cases of malignant melanoma, the effect of targeted treatment is lost over time. A research team from UZH and USZ has now discovered

June 27, 2024

AI outperforms radiologists in brain tumor diagnosis

As artificial intelligence advances, its uses and capabilities in real-world applications continue to reach new heights that may even surpass human expertise. In the field

October 1, 2024

Using ultrasound and AI to investigate the characteristics and healing trajectory of burn wounds

To provide the best care for injured service members, combat medics need reliable tools. To develop better tools, they call upon engineers.

August 11, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.